恩扎卢胺对前列腺癌患者吗啡暴露的影响
多中心两臂平行研究纳入24例前列腺癌患者,比较合用恩扎卢胺与未合用者的吗啡及吗啡-6-葡糖苷酸药代动力学。吗啡暴露无临床相关相互作用(GMR 1.01;90%CI 0.77-1.31),吗啡-6-葡糖苷酸暴露升高(GMR 1.77;90%CI 1.43-2.17)。结论为吗啡与恩扎卢胺可安全联用,建议低剂量起始并据疗效与耐受性滴定。
要点
- 恩扎卢胺不显著改变吗啡暴露,可安全联用
- 吗啡-6-葡糖苷酸暴露升高,临床意义可能有限
- 建议低剂量起始并依据疗效与耐受性滴定
核心结论
- 恩扎卢胺不影响吗啡暴露,但使吗啡-6-葡糖苷酸暴露升高,增量临床意义可能有限。
- 吗啡与恩扎卢胺可安全联用,建议低剂量起始并据疗效与耐受性滴定。
研究设计与样本
- 多中心两臂平行研究,24例前列腺癌男性,合用恩扎卢胺组12例、未合用组12例。
- 测定吗啡及其活性代谢物吗啡-6-葡糖苷酸的血浆浓度,采用非房室分析计算药代动力学参数。
- 计算血浆浓度-时间曲线下面积的几何均值比(GMR),以GMR的90%CI落在0.5-2.0内定义无临床相关相互作用。
主要发现
- 吗啡暴露两组相似,GMR 1.01(90%CI 0.77-1.31),90%CI落在0.5-2.0范围内。
- 吗啡-6-葡糖苷酸暴露在合用恩扎卢胺时升高,GMR 1.77(90%CI 1.43-2.17)。
关键数值与推荐
- 无临床相关相互作用的判定标准:吗啡GMR的90%CI在0.5-2.0范围内。
- 吗啡GMR 1.01(90%CI 0.77-1.31);吗啡-6-葡糖苷酸GMR 1.77(90%CI 1.43-2.17)。
临床怎么用
- 前列腺癌患者接受恩扎卢胺治疗时,吗啡可用于疼痛管理,无需因相互作用避免联用。
- 联用时建议吗啡低剂量起始,并根据疗效与耐受性进行滴定。
局限性
- 吗啡-6-葡糖苷酸的效价尚无定论,且其透过血脑屏障的能力不确定。
- 样本量较小(每组12例),可能限制统计效能与结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Pain management in patients with prostate cancer receiving enzalutamide is challenging owing to its high potential for drug-drug interactions. Morphine is generally preferred because of its favorable metabolic profile, but the effect of enzalutamide on the pharmacokinetics of morphine is unclear. The objective of this study was to assess whether a drug-drug interaction exists between enzalutamide and morphine in patients with prostate cancer. METHODS: In a multicenter two-arm parallel study, 24 men with prostate cancer received morphine with enzalutamide (n = 12) and without enzalutamide (n = 12). Plasma concentrations of morphine and its active metabolite morphine-6-glucuronide were measured. Pharmacokinetic parameters were calculated using a non-compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration-time curves were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR of morphine was within the range of 0.5-2.0. RESULTS: Morphine exposure was similar between both groups, with the 90% CI falling within the range of 0.5-2.0 (GMR 1.01; 90% CI 0.77-1.31). The exposure of morphine-6-glucuronide was increased with enzalutamide (GMR 1.77; 90% CI 1.43-2.17). CONCLUSIONS: The exposure of morphine was unaffected by enzalutamide, while morphine-6-glucuronide exposure was increased. Because of the inconclusive potency of morphine-6-glucuronide and its uncertain ability to cross the blood-brain barrier, the increase is likely of modest clinical significance. Therefore, morphine and enzalutamide can be safely combined when starting at a low dose and titrated based on efficacy and tolerability. CLINICAL TRIAL REGISTRATION: NCT05339672.
引用
- Op 't Hoog CJP, Mehra N, van der Weij B, et al. Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer. Clin Pharmacokinet. 2026. PMID: 42081083. doi:10.1007/s40262-026-01640-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。